[go: up one dir, main page]

MX2018014631A - Formulacion de neurotoxina. - Google Patents

Formulacion de neurotoxina.

Info

Publication number
MX2018014631A
MX2018014631A MX2018014631A MX2018014631A MX2018014631A MX 2018014631 A MX2018014631 A MX 2018014631A MX 2018014631 A MX2018014631 A MX 2018014631A MX 2018014631 A MX2018014631 A MX 2018014631A MX 2018014631 A MX2018014631 A MX 2018014631A
Authority
MX
Mexico
Prior art keywords
tryptophan
tyrosine
liquid
amino acid
free
Prior art date
Application number
MX2018014631A
Other languages
English (en)
Other versions
MX392529B (es
Inventor
Jarstad Anders
FRIIS Anna
Stahl Ulf
GURELL Ann
Agren Barbro
EDSTROM Emilia
Pickett Andrew
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of MX2018014631A publication Critical patent/MX2018014631A/es
Publication of MX392529B publication Critical patent/MX392529B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a formulaciones de neurotoxinas líquidas estables que están libres de proteínas de origen animal, que comprenden un agente surfactante, un aminoácido seleccionado a partir de triptófano y tirosina, un amortiguador que comprende iones sodio, cloruro y fosfato, que tienen un pH entre 5.5 y 8, los cuales son estables durante 2 meses. Estas composiciones son adecuadas para su uso en terapia y en particular para su administración a un paciente para lograr así un efecto estético o terapéutico deseado. La invención también se relaciona al uso de un aminoácido seleccionado a partir de triptófano y tirosina para proteger una neurotoxina proteica de la degradación en una composición líquida que esté libre de proteínas derivadas de animales.
MX2018014631A 2016-05-27 2017-05-26 Formulacion de neurotoxina. MX392529B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016062085 2016-05-27
PCT/EP2017/062785 WO2017203038A1 (en) 2016-05-27 2017-05-26 Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

Publications (2)

Publication Number Publication Date
MX2018014631A true MX2018014631A (es) 2019-06-12
MX392529B MX392529B (es) 2025-03-21

Family

ID=56289455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014631A MX392529B (es) 2016-05-27 2017-05-26 Formulacion de neurotoxina.

Country Status (32)

Country Link
US (5) US20190183988A1 (es)
EP (3) EP3463432B1 (es)
JP (1) JP7053498B2 (es)
KR (2) KR102423739B1 (es)
CN (2) CN109562148A (es)
AR (1) AR108631A1 (es)
AU (1) AU2017270359B2 (es)
BR (1) BR112018074311A2 (es)
CA (1) CA3025437A1 (es)
CY (2) CY1124237T1 (es)
DK (3) DK4026532T3 (es)
EA (1) EA038124B1 (es)
ES (2) ES2911124T3 (es)
GE (2) GEAP202014939A (es)
HR (2) HRP20220024T1 (es)
HU (2) HUE057640T2 (es)
IL (2) IL285190B (es)
LT (3) LT4026532T (es)
MX (1) MX392529B (es)
NZ (1) NZ788585A (es)
PL (2) PL3463432T3 (es)
PT (2) PT3679946T (es)
RS (3) RS61340B1 (es)
RU (1) RU2741497C9 (es)
SA (1) SA518400513B1 (es)
SG (1) SG11201810561YA (es)
SI (2) SI3463432T1 (es)
SM (3) SMT202500479T1 (es)
TW (1) TWI777955B (es)
UA (1) UA123679C2 (es)
WO (1) WO2017203038A1 (es)
ZA (1) ZA201807904B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
SMT201800215T1 (it) 2008-12-31 2018-05-02 Revance Therapeutics Inc Formulazioni iniettabili di tossina botulinica domanda di brevetto correlata
KR101975051B1 (ko) 2009-06-25 2019-05-03 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
RU2020123346A (ru) * 2017-12-20 2022-01-20 Аллерган, Инк. Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для лечения расстройств, связанных с фиброзом
UY38744A (es) * 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
CN116440281A (zh) * 2022-01-07 2023-07-18 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物
GEAP202416580A (en) * 2022-01-14 2024-11-25 Ipsen Biopharm Ltd Treatment of moderate to very severe glabellar lines and lateral canthal lines
JP2025504249A (ja) * 2022-02-15 2025-02-06 メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー 液体ボツリヌス毒素製剤及びその使用
TW202525330A (zh) 2023-08-10 2025-07-01 德商梅茲製藥有限兩合公司 液體肉毒桿菌毒素製劑及其製作方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
EP1253932B1 (en) 2000-02-08 2005-04-27 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP1260230A4 (en) * 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd LONG-TERM STABILIZED PREPARATIONS
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
CN101005853B (zh) 2004-07-26 2011-05-04 莫茨药物股份两合公司 包含肉毒杆菌神经毒素的治疗组合物
EP1778279B1 (en) * 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
RU2440825C2 (ru) * 2007-07-10 2012-01-27 Меди-Токс, Инк. Жидкая фармацевтическая композиция ботулинического токсина
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
LT2715355T (lt) 2011-06-01 2017-06-12 Biomadison, Inc. Ne fret (fluorescencijos rezonansinės energijos perdavimas) būdu atliekamas botulino tyrimas
CN103958747B (zh) 2011-09-29 2017-03-01 塞尔斯纳普有限责任公司 用于产毒性测试的组合物和方法
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
WO2015044416A1 (en) 2013-09-30 2015-04-02 Galderma S.A. Prostate cancer treatment
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins

Also Published As

Publication number Publication date
DK3463432T3 (da) 2021-01-04
PT3679946T (pt) 2022-01-14
BR112018074311A2 (pt) 2019-10-01
US20190183988A1 (en) 2019-06-20
RU2741497C9 (ru) 2021-04-30
SMT202500479T1 (it) 2026-01-12
HRP20220024T1 (hr) 2022-04-01
ES2846350T3 (es) 2021-07-28
AR108631A1 (es) 2018-09-12
GEAP202014939A (en) 2020-04-10
DK3679946T3 (da) 2022-02-07
EP3463432B1 (en) 2020-10-07
AU2017270359B2 (en) 2023-09-21
RU2741497C2 (ru) 2021-01-26
LT4026532T (lt) 2026-01-12
US20250255943A1 (en) 2025-08-14
US20230190892A9 (en) 2023-06-22
CY1124916T1 (el) 2023-01-05
SI3463432T1 (sl) 2021-02-26
CN109562148A (zh) 2019-04-02
EP3679946A1 (en) 2020-07-15
HRP20202070T1 (hr) 2021-02-19
HUE052023T2 (hu) 2021-04-28
EA201892493A1 (ru) 2019-04-30
PL3679946T3 (pl) 2022-05-30
KR102423739B1 (ko) 2022-07-21
PL3463432T3 (pl) 2021-04-19
JP7053498B2 (ja) 2022-04-12
GEP20207139B (en) 2020-07-27
HUE057640T2 (hu) 2022-05-28
KR20190022548A (ko) 2019-03-06
TW201742632A (zh) 2017-12-16
IL285190A (en) 2021-08-31
IL285190B (en) 2022-07-01
US20230181702A1 (en) 2023-06-15
RS67508B1 (sr) 2025-12-31
SMT202200080T1 (it) 2022-03-21
CN111701010B (zh) 2023-09-26
WO2017203038A1 (en) 2017-11-30
RS61340B1 (sr) 2021-02-26
US20240050539A1 (en) 2024-02-15
US20210330765A1 (en) 2021-10-28
IL263173A (en) 2018-12-31
JP2019517481A (ja) 2019-06-24
US12285468B2 (en) 2025-04-29
SG11201810561YA (en) 2018-12-28
ES2911124T3 (es) 2022-05-17
UA123679C2 (uk) 2021-05-12
LT3679946T (lt) 2022-02-10
MX392529B (es) 2025-03-21
EA038124B1 (ru) 2021-07-09
RS62832B1 (sr) 2022-02-28
NZ788585A (en) 2025-12-19
SMT202100003T1 (it) 2021-03-15
EP4026532B1 (en) 2025-11-26
KR20220054887A (ko) 2022-05-03
EP4026532A1 (en) 2022-07-13
TWI777955B (zh) 2022-09-21
CY1124237T1 (el) 2022-07-22
EP3679946B1 (en) 2022-01-05
AU2017270359A1 (en) 2018-12-13
LT3463432T (lt) 2021-01-25
DK4026532T3 (da) 2025-12-08
CA3025437A1 (en) 2017-11-30
PT3463432T (pt) 2021-01-12
NZ748626A (en) 2025-05-02
RU2018142149A3 (es) 2020-07-23
EP3463432A1 (en) 2019-04-10
SI3679946T1 (sl) 2022-04-29
RU2018142149A (ru) 2020-06-29
ZA201807904B (en) 2020-05-27
IL263173B (en) 2021-08-31
KR102399451B1 (ko) 2022-05-23
SA518400513B1 (ar) 2022-11-03
CN111701010A (zh) 2020-09-25

Similar Documents

Publication Publication Date Title
MX2018014631A (es) Formulacion de neurotoxina.
MX2021006150A (es) Lípidos con amina modificados.
MX2021003455A (es) Lípidos con amina ionizables.
CL2017002488A1 (es) Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012)
IN2015MU00865A (es)
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
TR200801336T1 (tr) Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
MX2017010220A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
EA201190286A1 (ru) Адъювантные композиции, содержащие неионный агент, обеспечивающий изотоничность
BR0210057A (pt) Composição compreendendo agentes antifúngicos para tratar vulvovaginite e vaginose
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
PE20070437A1 (es) FORMULACION ACUOSA hFSH
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
PH12020551500A1 (en) Viscosity reduction of highly concentrated protein formulations
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
ZA202102816B (en) High concentration protein formulation
PH12020550239A1 (en) Periodontitis vaccine and related compositions and methods of use
BR112022008655A2 (pt) Composições de copolímero em bloco responsivas ao ph, micelas, e métodos de uso
BR112022004674A2 (pt) Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas
BR112021025545A2 (pt) Formulações de penetração transdérmica
ZA202203563B (en) Pediatric suspension formulation